

RAG-Stiftung converts bond and increases shareholding to 9.8%



(SIX: SFZN) In the third quarter of 2015, the RAG-Stiftung Beteiligungsgesellschaft mbH (RSBG), based in Essen, Germany, participated in the financing of the acquisition of substantial parts of BASF's pharmaceutical supply business by means of a privately placed hybrid convertible bond issued by Siegfried Holding AG amounting to CHF 60 million. The hybrid convertible bond entitled RAG-Stiftung Beteiligungsgesellschaft mbH to convert the bond into Siegfried Holding AG shares.

RAG-Stiftung Beteiligungsgesellschaft mbH exercised the conversion option on 2 October 2017 and as a result will own about 9.8% of the Zofingen-based company. The conversion does not require an increase of Siegfried Holding AG's share capital as it will be satisfied out of treasury shares of the company.

Siegfried CEO Rudolf Hanko: "By significantly increasing its existing shareholding in our company, RAG-Stiftung Beteiligungsgesellschaft mbH as a stable partner demonstrates its trust in the Siegfried Group's continued development."

Contact

Dr. Reto Suter
Chief Financial Officer
reto.suter@siegfried.ch
Tel. +41 62 746 11 35

Siegfried Holding AG
Untere Bruehlstrasse 4
CH-4800 Zofingen

This Media Release on the web

<http://www.siegfried.ch/media-releases/>

About Siegfried

The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, the USA, Malta, China, Germany and France. Siegfried reported sales of CHF 718 million for the financial year 2016 and currently employs approximately 2300 employees at nine locations on three continents. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).

Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediates and controlled substances, and provides development and production services for finished dosage forms including sterile filling.

Cautionary Statements Regarding Forward-Looking Statements

This press release may contain forward-looking statements based on current assumptions and forecasts made by Siegfried Group management and other information currently available to the Siegfried Group. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Siegfried Holding AG does not intend, and does not assume any liability whatsoever, to update these forward-looking statements or to conform them to future events or developments.